Categories

Semaglutide Impurities, des-20-1-AEEA-SMT

The semaglutide impurity des-20-1-AEEA-SMT is a specific structural defect produced during the synthesis or degradation of semaglutide. Semaglutide is a GLP-1 receptor agonist, mainly used to treat type 2 diabetes and obesity. The impurity lacks the 1-AEEA modification fragment at the 20th position, which may affect the biological activity and stability of the drug. Strict monitoring of such impurities is of great significance to ensure the quality and safety of drugs.

  • Product Details

  • Technical Support

Product Overview

Basic Description

Structure and function:
1. des-20-1-AEEA-SMT is an impurity of semaglutide that lacks the first AEEA modification at lysine 20.
2. It is a GLP-1 receptor agonist that regulates blood glucose levels by mimicking intestinal secretion of glucagon-like peptide-1 (GLP-1).
3. Due to the lack of a modified moiety, its biological activity and pharmacokinetic properties may differ from those of semaglutide.
In vitro and in vivo studies:
1. In vitro studies have shown that des-20-1-AEEA-SMT is still able to bind to and activate the GLP-1 receptor, but its affinity and potency may be reduced.
2. In vivo studies have shown that the hypoglycemic effect of this impurity in animal models is weaker than that of semaglutide, and its half-life may be shorter.
3. Preclinical studies have shown that des-20-1-AEEA-SMT may cause adverse reactions or reduced efficacy in some cases.

​Three-letter sequence​

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys(AEEA-γ-Glu-Octadecanedioic Acid)-Ile-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2

​Single letter sequence​

HHAEGTFTSDVSSYLEGQAK(AEEA-γ-Glu-Octadecanedioic Acid)ITWLVLVKGDVRRAARRRRG-NH2

Molecular formula

C185H290N49O57S

Molecular weight

4062.17 g/mol

Product Attributes

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light


Instructions
  • Please store the product immediately according to the recommended conditions in the instructions upon receipt. Unless otherwise specified, all products are freeze-dried powders. Since trace amounts of peptides are deposited in the tube during the freeze-drying process, forming a very thin or invisible peptide layer, we recommend centrifuging at about 8,000-12,000g for 10-30 seconds in a centrifuge before opening the tube cap, so that the peptides attached to the tube cap or tube wall are aggregated at the bottom of the tube.
  • Please refer to relevant literature for the specific optimal working concentration, or explore and optimize through experiments based on the purpose of the experiment and specific cells and animals.
Our company can provide customized synthesis of high-polypeptide, virtual screening of compounds, Animal disease model construction,
Drug safety verification,
Application technology support for gene editing animals, etc.
For specific application consultation, please contact the sales department.

We look forward to your inquiries:

Sales Department 1: Manager Han
Mobile phone: 18701856899
WeChat: 18701856899
QQ: 1295139147
Email: 18701856899@163.com